[ Iterum Therapeutics raises $65M in Series B ]

Iterum Therapeutics has raised $65 million in Series B funding.

Founded in 2015, Iterum Therapeutics  is a clinical-stage pharmaceutical company that focuses on the development and commercialization of anti-infectives for patients with infectious diseases and other acute illnesses.

The proceeds of this financing will be used to complete a Phase 3 pivotal trial in uUTI and to advance the broader Phase 3 pivotal program. Trials are expected to begin in the first half of 2018 and Iterum plans to file an NDA with the FDA by year end 2019.

Funding  Series B
Founded  2015
Country  Ireland
City  Dublin
Founder / CEO  Corey Fishman
Deal Size  $65M
Investors  Arix Bioscience
 Frazier Healthcare Partners
 Canaan Partners
 Sofinnova Ventures
 New Leaf Venture Partners
 Bay City Capital
 Pivotal bioVenture Partners
 Domain Associates
 Advent Life Sciences
Previous Investors  Sofinnova Ventures
 Canaan Partners
 Frazier Healthcare Partners
 New Leaf Venture Partners

Investor & Serial Startupper ;-))

Leave a Reply

Password must be at least 7 characters long.
Please login to view this page.
Please login to view this page.
Please login to view this page.